Notice: This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CNAT vs. RDHL, APVO, SPRC, SNPX, PPBT, PBM, CNSP, NBY, GNPX, and ATNFShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include RedHill Biopharma (RDHL), Aptevo Therapeutics (APVO), SciSparc (SPRC), Synaptogenix (SNPX), Purple Biotech (PPBT), Psyence Biomedical (PBM), CNS Pharmaceuticals (CNSP), NovaBay Pharmaceuticals (NBY), Genprex (GNPX), and 180 Life Sciences (ATNF). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. RedHill Biopharma Aptevo Therapeutics SciSparc Synaptogenix Purple Biotech Psyence Biomedical CNS Pharmaceuticals NovaBay Pharmaceuticals Genprex 180 Life Sciences RedHill Biopharma (NASDAQ:RDHL) and Conatus Pharmaceuticals (NASDAQ:CNAT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking. Does the MarketBeat Community believe in RDHL or CNAT? Conatus Pharmaceuticals received 110 more outperform votes than RedHill Biopharma when rated by MarketBeat users. Likewise, 79.67% of users gave Conatus Pharmaceuticals an outperform vote while only 66.41% of users gave RedHill Biopharma an outperform vote. CompanyUnderperformOutperformRedHill BiopharmaOutperform Votes42766.41% Underperform Votes21633.59% Conatus PharmaceuticalsOutperform Votes53779.67% Underperform Votes13720.33% Is RDHL or CNAT more profitable? RedHill Biopharma has a net margin of 0.00% compared to Conatus Pharmaceuticals' net margin of -52.42%. RedHill Biopharma's return on equity of 0.00% beat Conatus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets RedHill BiopharmaN/A N/A N/A Conatus Pharmaceuticals -52.42%-48.22%-39.32% Does the media refer more to RDHL or CNAT? In the previous week, RedHill Biopharma had 3 more articles in the media than Conatus Pharmaceuticals. MarketBeat recorded 3 mentions for RedHill Biopharma and 0 mentions for Conatus Pharmaceuticals. RedHill Biopharma's average media sentiment score of 0.30 beat Conatus Pharmaceuticals' score of 0.00 indicating that RedHill Biopharma is being referred to more favorably in the media. Company Overall Sentiment RedHill Biopharma Neutral Conatus Pharmaceuticals Neutral Which has more volatility & risk, RDHL or CNAT? RedHill Biopharma has a beta of 3.84, indicating that its share price is 284% more volatile than the S&P 500. Comparatively, Conatus Pharmaceuticals has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Do institutionals & insiders have more ownership in RDHL or CNAT? 7.2% of RedHill Biopharma shares are held by institutional investors. Comparatively, 15.2% of Conatus Pharmaceuticals shares are held by institutional investors. 6.8% of RedHill Biopharma shares are held by company insiders. Comparatively, 11.3% of Conatus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, RDHL or CNAT? RedHill Biopharma has higher earnings, but lower revenue than Conatus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedHill Biopharma$3.71M0.96$23.92MN/AN/AConatus Pharmaceuticals$21.72M0.04-$11.39MN/AN/A SummaryRedHill Biopharma beats Conatus Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Remove Ads Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$929,000.00$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-0.097.1723.3318.67Price / Sales0.04220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book0.056.396.894.23Net Income-$11.39M$142.12M$3.20B$247.15M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.03flatN/A-92.2%$929,000.00$21.72M-0.0930RDHLRedHill Biopharma0.5013 of 5 stars$3.01+17.6%N/A-99.2%$3.86M$3.71M0.00210Short Interest ↑APVOAptevo Therapeutics2.2043 of 5 stars$2.64+9.5%$10,952.00+414,748.5%-100.0%$3.85M$3.11M0.0050Short Interest ↑Gap DownSPRCSciSparc0.3542 of 5 stars$0.37-1.1%N/A-82.6%$3.84M$1.75M0.004Short Interest ↑Gap DownSNPXSynaptogenix2.1801 of 5 stars$2.80+2.9%$14.00+400.0%-42.8%$3.80MN/A0.004PPBTPurple Biotech2.4849 of 5 stars$2.80+2.6%$33.00+1,078.6%N/A$3.73MN/A-0.3220Gap UpPBMPsyence BiomedicalN/A$0.72-8.1%N/A-99.3%$3.55MN/A0.00N/AShort Interest ↓CNSPCNS Pharmaceuticals1.8728 of 5 stars$3.06-1.9%$25.00+717.0%-99.9%$3.52MN/A-0.045Analyst ForecastShort Interest ↓NBYNovaBay Pharmaceuticals1.5348 of 5 stars$0.64+2.3%$0.85+31.9%-83.4%$3.41M$13.84M-0.0130Analyst ForecastGap UpGNPXGenprex4.4193 of 5 stars$0.40+10.1%$10.00+2,400.0%-90.9%$3.40MN/A0.0020Short Interest ↓News CoveragePositive NewsGap UpATNF180 Life SciencesN/A$1.07flatN/A-55.8%$3.40MN/A0.007Short Interest ↑ Remove Ads Related Companies and Tools Related Companies RedHill Biopharma Competitors Aptevo Therapeutics Competitors SciSparc Competitors Synaptogenix Competitors Purple Biotech Competitors Psyence Biomedical Competitors CNS Pharmaceuticals Competitors NovaBay Pharmaceuticals Competitors Genprex Competitors 180 Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNAT) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
